Cellulærimmunologiske og cellebiologiske studiar ved Akutt myelogen leukemi (AML). Delprosjekt: Kjemikinnettverk ved AML.
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Haematologica 2007 Mar;92(3):332-41.
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
Eur J Haematol 2007 Sep;79(3):210-25. Epub 2007 jul 26
T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).
Cancer Immunol Immunother 2006 Jul;55(7):830-40. Epub 2005 nov 3
Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.
Haematologica 2004 Apr;89(4):391-402.
In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts.
Int J Cancer 2004 Oct;111(6):858-67.
Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts.
Eur J Haematol 2004 Nov;73(5):340-50.
In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release
Journal of Interferon & Cytokine Research. Akseptert.
The Immunological Dilemma: Innate and Adaptive Immune Response versus Human Acute Myeloid Leukemia.
Open Hematology Reviews 2007, 1, 1-14.
The protein kinase C agonist PEP005 alters regulation of gene transcription, induces differentiation and increases constitutive
ISEH konferanse, Hamburg 2007.
Risk of infections in hospitalized patients receiving intensive chemotherapy for hematologic malignancies. Immunological charact
- november 2004